Early pregnancy IGF-I and placental GH and risk of epithelial ovarian cancer: A nested case-control study

International Journal of Cancer

Volumn 137, Issue 2, 2015, Pages 439-447

  Schock, Helena ^a,b   Fortner, Renée T ^a   Surcel, Heljä Marja ^c   Grankvist, Kjell ^b   Pukkala, Eero ^d,e   Lehtinen, Matti ^e   Lundin, Eva ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UMEÅ UNIVERSITY   (Sweden)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d FINNISH CANCER REGISTRY   (Finland)

^e UNIVERSITY OF TAMPERE   (Finland)

Author keywords

IGF I; ovarian neoplasms; placental GH; pregnancy; prospective studies

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C; PLACENTAL PEPTIDE HORMONE;

ADULT; ARTICLE; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; ENDOMETRIUM TUMOR; FEMALE; FIRST TRIMESTER PREGNANCY; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; TUMOR INVASION; ADOLESCENT; META ANALYSIS (TOPIC); METABOLISM; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; ODDS RATIO; OVARIAN NEOPLASMS; PREGNANCY; RISK FACTOR; STATISTICAL MODEL; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LOGISTIC MODELS; META-ANALYSIS AS TOPIC; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; ODDS RATIO; OVARIAN NEOPLASMS; PLACENTAL HORMONES; PREGNANCY; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84929281276     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29387     Document Type: Article

References (47)

1. Ferlay J, Soerjomataram I, Ervik M, et al. Globocan 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, 2014.
2. Prat J., Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Archiv 2012; 460: 237-49.
3. Hunn J, Rodriguez GC., Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol 2012; 55: 3-23.
4. Risch HA., Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998; 90: 1774-86.
5. Chhabra Y, Waters MJ, Brooks AJ., Role of the growth hormone-IGF-1 axis in cancer. Expert Opin Ther Targets 2011; 6: 71-84.
6. Perry JK, Emerald BS, Mertani HC, et al. The oncogenic potential of growth hormone. Growth Horm IGF Res 2006; 16: 277-89.
7. Hull KL, Harvey S., Growth hormone: roles in female reproduction. J Endocrinol 2001; 168: 1-23.
8. Kwintkiewicz J, Giudice LC., The interplay of insulin-like growth factors, gonadotropins, and endocrine disruptors in ovarian follicular development and function. Semin Reprod Med 2009; 27: 43-51.
9. Chellakooty M, Vangsgaard K, Larsen T, et al. A longitudinal study of intrauterine growth and the placental growth hormone (GH)-insulin-like growth factor I axis in maternal circulation: association between placental GH and fetal growth. J Clin Endocrinol Metab 2004; 89: 384-91.
10. Bruchim I, Werner H., Targeting IGF-1 signaling pathways in gynecologic malignancies. Expert Opin Ther Targets 2013; 17: 307-20.
11. Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346-53.
12. Beauchamp MC, Yasmeen A, Knafo A, et al. Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol 2010; 2010: 257058.
13. Karasik A, Menczer J, Pariente C, et al. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 1994; 78: 271-6.
14. Huang YF, Cheng WF, Wu YP, et al. Circulating IGF system and treatment outcome in epithelial ovarian cancer. Endocr Relat Cancer 2014; 21: 217-29.
15. Olausson H, Lof M, Brismar K, et al. Longitudinal study of the maternal insulin-like growth factor system before, during and after pregnancy in relation to fetal and infant weight 17. Horm Res 2008; 69: 99-106.
16. Monaghan JM, Godber IM, Lawson N, et al. Longitudinal changes of insulin-like growth factors and their binding proteins throughout normal pregnancy. Ann Clin Biochem 2004; 41: 220-6.
17. Clapp JF, III, Schmidt, S, Paranjape, A, et al. Maternal insulin-like growth factor-I levels (IGF-I) reflect placental mass and neonatal fat mass. Am J Obstet Gynecol 2004; 190: 730-6.
18. Lukanova A, Lundin E, Toniolo P, et al. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 2002; 101: 549-54.
19. Peeters PH, Lukanova A, Allen N, et al. Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2007; 14: 81-90.
20. Ose J, Fortner RT, Schock H, et al. Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort. Br J Cancer 2014. doi: 10.1038/bjc.2014.566.
21. Tworoger SS, Lee IM, Buring JE, et al. Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts. Cancer Epidemiol Biomarkers Prev 2007; 16: 1691-5.
22. Schock H, Surcel HM, Zeleniuch-Jacquotte A, et al. Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer. Endocr Relat Cancer 2014; 21: 831-44.
23. Lee KR, Tavassoli FA, Prat J, et al. Tumors of the ovary and peritoneum. In:, Tavassoli FA, Devilee P, eds. Pathology and genetics tumours of the breast and female genital organsed, vol. 1. Lyon: IARC Press, 2003. 113 -202.
24. Chen VW, Ruiz B, Killeen JL, et al. Pathology and classification of ovarian tumors. Cancer 2003; 97: 2631-42.
25. Leung KC, Johannsson G, Leong GM, et al. Estrogen regulation of growth hormone action. Endocr Rev 2004; 25: 693-721.
26. Whitehead A, Whitehead J., A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991; 10: 1665-77.
27. Cleveland WS, Loader C., Smoothing by local regression: principles and methods. In:, Hrdle W, Schimek MG, eds. Statistical theory and computational aspects of smoothing. Heidelberg: Physica-Verlag, 1996. 10 -49.
28. DerSimonian R, Laird N., Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
29. Higgins JP, Thompson SG., Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
30. Frankenne F, Closset J, Gomez F, et al. The physiology of growth hormones (GHs) in pregnant women and partial characterization of the placental GH variant. J Clin Endocrinol Metab 1988; 66: 1171-80.
31. Fuglsang J, Ovesen P., Aspects of placental growth hormone physiology. Growth Horm IGF Res 2006; 16: 67-85.
32. Lonberg U, Damm P, Andersson AM, et al. Increase in maternal placental growth hormone during pregnancy and disappearance during parturition in normal and growth hormone-deficient pregnancies. Am J Obstet Gynecol 2003; 188: 247-51.
33. Caufriez A, Frankenne F, Hennen G, et al. Regulation of maternal IGF-I by placental GH in normal and abnormal human pregnancies. Am J Physiol 1993; 265: E572-E7.
34. Mirlesse V, Frankenne F, Alsat E, et al. Placental growth hormone levels in normal pregnancy and in pregnancies with intrauterine growth retardation. Pediatr Res 1993; 34: 439-42.
35. Caufriez A, Frankenne F, Englert Y, et al. Placental growth hormone as a potential regulator of maternal IGF-I during human pregnancy. Am J Physiol 1990; 258: E1014-E9.
36. Pollak M., Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-28.
37. Persechini ML, Gennero I, Grunenwald S, et al. Decreased IGF-1 concentration during the first trimester of pregnancy in women with normal somatotroph function. Pituitary 2014.
38. The endocrinology of pregnancy. In:, Fritz MAS, Speroff L., Clinical gynecologic endocrinology and infertility, 8th ed. Lippincott Williams & Wilkins, a Wolters Kluwer Business, 2011. 269-330.
39. Jenkins PJ., Acromegaly and cancer. Horm Res 2004; 62 Suppl 1: 108-15.
40. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Science Transl Med 2011; 3: 70ra13.
41. Papadia A, Schally AV, Halmos G, et al. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer. Horm Metab Res 2011; 43: 816-20.
42. Klukovits A, Schally AV, Szalontay L, et al. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers. Cancer 2012; 118: 670-80.
43. Khandwala HM, McCutcheon IE, Flyvbjerg A, et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21: 215-44.
44. Brokaw J, Katsaros D, Wiley A, et al. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 2007; 25: 346-54.
45. Lukanova A, Toniolo P, Akhmedkhanov A, et al. A cross-sectional study of IGF-I determinants in women. Eur J Cancer Prev 2001; 10: 443-52.
46. Blackmore KM, Wong J, Knight JA., A cross-sectional study of different patterns of oral contraceptive use among premenopausal women and circulating IGF-1: implications for disease risk. BMC Womens Health 2011; 11: 15.
47. Holl K, Lundin E, Kaasila M, et al. Effect of long-term storage on hormone measurements in samples from pregnant women: the experience of the Finnish Maternity Cohort. Acta Oncol 2008; 47: 406-12.